Erratum: IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer (Cancer Gene Therapy (2001) 14, (819-827) DOI: 10.1038/sj.cgt.7701069);IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer

Cancer Gene Therapy

Volumn 14, Issue 10, 2007, Pages 819-827

  Wang, H ^a   Yang, G ^a   Timme, T L ^a   Fujita, T ^a   Naruishi, K ^a   Frolov, A ^a   Brenner, M K ^b   Kadmon, D ^a   Thompson, T C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Bone marrow cells; Cancer vaccination; Gene therapy; IL 12; Metastasis

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FLUOROURACIL; INTERLEUKIN 12; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE METASTASIS; CANCER IMMUNIZATION; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL BASED GENE THERAPY; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG EFFICACY; FLOW CYTOMETRY; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG METASTASIS; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALIA;

EID: 34548620144     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701084     Document Type: Erratum

References (39)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565.
3. Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005; 28: 389-395.
4. Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116: 415-421.
5. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36: 129-138.
6. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 2004; 27: 240-253.
7. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004; 53: 431-438.
8. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004; 16: 130-136.
9. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
10. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409-417.
11. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 2002; 51: 351-357.
12. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21: 3343-3350.
13. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
14. Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J et al. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther 2001; 1: 481-495.
15. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7: 515-523.
16. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12: 1955-1967.
17. Gdor Y, Timme TL, Miles BJ, Kadmon D, Thompson TC. Gene therapy for prostate cancer. Expert Rev Anticancer Ther 2002; 2: 309-321.
18. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy 1999; 6: 338-349.
19. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB et al. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 2003; 4: 251-261.
20. Green NK, Seymour LW. Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther 2002; 9: 1036-1042.
21. Friedrich G, Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev 1991; 5: 1513-1523.
22. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA et al. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene 1995; 10: 869-879.
23. Tahara H, Zitvogel L, Storkus WJ, Zeh III HJ, McKinney TG, Schreiber RD et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
24. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927-1933.
25. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
26. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
27. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996; 93: 11798-11801.
28. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001; 194: 1195-1205.
29. Jacobsen SE. IL12, a direct stimulator and indirect inhibitor of haematopoiesis. Res Immunol 1995; 146: 506-514.
30. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999; 27: 58-63.
31. Xu YX, Gao X, Janakiraman N, Chapman RA, Gautam SC. IL-12 gene therapy of leukemia with hematopoietic progenitor cells without the toxicity of systemic IL-12 treatment. Clin Immunol 2001; 98: 180-189.
32. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59: 4035-4041.
33. Stewart FM, Crittenden RB, Lowry PA, Pearson-White S, Quesenberry PJ. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 1993; 81: 2566-2571.
34. Stewart FM, Zhong S, Wuu J, Hsieh C, Nilsson SK, Quesenberry PJ. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 1998; 91: 3681-3687.
35. Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM. et al. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003; 101: 1645-1652.
36. Bubnic SJ, Keating A. Donor stem cells home to marrow efficiently and contribute to short- and long-term hematopoiesis after low-cell-dose unconditioned bone marrow transplantation. Exp Hematol 2002; 30: 606-611.
37. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
38. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111-1116.
39. Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001; 97: 1951-1959.